Search Within

Anas Younes

Formats
  1. Meeting Abstract (153)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (320)
  2. Department of Medicine (320)
  3. Executive Committee, Center for Hematologic Malignancies (320)
  4. Hematologic Malignancies, Division of (320)
  5. Lymphoma (320)
  6. Hematology-Oncology Fellows (98)

More Groups

People
  1. Andrew Zelenetz (89)
  2. Connie Batlevi (81)
  3. David Straus (74)
  4. Matthew Matasar (68)
  5. Anita Kumar (67)
  6. Paul Hamlin (67)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (91)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (320)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • AFM13: An antigen specific immunotherapy for the treatment of CD30+ malignancies: Results of first-in-man study in relapsed/refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Rothe, A.; Reiners, K. S.; Topp, M. S.; Younes, A.; von Tresckow, B.; Hummel, H. D.; Kessler, J.; Ravic, M.; Marschner, J. P.; von Strandmann, E. P.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies
    Meeting Abstract

    Ma, A. W.; Atoyan, R.; Younes, A.; Flinn, I. W.; Oki, Y.; Copeland, A.; Berdeja, J. G.; Laliberte, R.; Viner, J.; Samson, M. E. S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3
    Meeting Abstract

    Hong, D.; Kim, Y.; Younes, A.; Nemunaitis, J.; Fowler, N.; Hsu, J.; Zhou, T. Y.; Fayad, L.; Zhang, N.; Piha-Paul, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • An open-label phase II study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular ymphoma
    Meeting Abstract

    Younes, A.; Salles, G.; Bociek, R. G.; Martinelli, G.; Caballero, D.; Barca, E. G.; Mukherjee, N.; Williams, L.; Herbst, F.; Tavorath, R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Targeted therapy of B cell lymphoma with a direct inhibitor of the NF-kappa B subunit c-Rel
    Meeting Abstract

    Shono, Y.; Tuckett, A. Z.; Liou, H. C.; Ouk, S.; Doubrovina, E.; Doubrovin, M.; Derenzini, E.; Scallion, M. I.; Tsai, J. J.; Smith, O. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A comprehensive clinical next generation sequencing-based assay can impact hematopathologic diagnosis in a significant subset of patients with hematologic malignancies
    Meeting Abstract

    Pichardo, J. D.; Feldstein, J. T.; Arcila, M.; Batlevi, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.; Tallman, M. S.; Stein, E. M.; Klimek, V. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
    Meeting Abstract

    Oki, Y.; Fanale, M. A.; Romaguera, J. E.; Fayad, L.; Fowler, N.; Copeland, A. R. M.; Samaniego, F.; Kwak, L. W.; Neelapu, S. S.; Wang, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save